Moderna, Inc.Cambridge, Massachusetts, United States
Disclosure information not submitted.
223 - Safety, Tolerability, and Immunogenicity of the mRNA-1345 RSV Vaccine in Solid Organ Transplant Recipients Aged ≥18 Years
Monday, October 20, 20254:15 PM - 4:27 PM US ET
563 - Safety and Immunogenicity of mRNA-1273.815 in COVID-19 Vaccine-Naïve Children 2 Through 4 Years of Age: Results From a Phase 3, Open-Label Trial
Wednesday, October 22, 202511:06 AM - 11:18 AM US ET
